I am the Director of Barts Cancer Institute. My groups’ primary research interests are in the genomics and molecular pathology of pancreatic cancer and the development of oncolytic virotherapy.
My key area of interest is in cancer and the tumour microenvironment, especially in ovarian cancer. I study the links between cancer and inflammation and research ways of translating this to clinical trials.
I am John Snow Professor of Epidemiology at Queen Mary University of London. My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening.
My research activities are concentrated on cancer screening and early diagnosis. There is potential for considerable saving of lives from cancer if it were diagnosed at an earlier stage.
My research group works on molecular pathology, genetics and progression of leukaemia and lymphomas, aiming to improve on current diagnostic, prognostic and treatment strategies.
Our research aims to improve the efficacy of standard of care immunotherapy, chemotherapy and radiotherapy in human solid cancers by understanding the molecular mechanisms underlying tumour stromal contributions to tumour growth and therapy efficacy.
My clinical research interests include tissue banking, clinical trials, innovative surgical techniques, epidemiology, meta-analysis and patient care pathways. My translational research interests include pancreatic cancer stroma and tumour-stroma cross-talk including cell signalling, adhesion, metastasis and invasion.
My research interests are focused on Targeted Precision Prevention. This includes population-based genetic testing, mainstreaming genetic testing and approaches for risk prediction, population stratification, targeted screening, cancer prevention and cost-effectiveness analyses.
I study the biology of tumour invasion with a particular focus on the roles of the adhesion molecules expressed on the cell surface that mediate this process. Our group concentrates on the study of integrins that are the principal family of adhesion molecules that mediate the interaction between cells and the extracellular matrix.
My group’s work focuses on the role of the tumour suppressor protein LIMD1 and its family members Ajuba and WTIP and how their deregulation in normal tissue contributes to the development of lung, renal and breast cancer.
My lab aims to understand the basic mechanisms controlling DNA replication in mammalian cells and how disruption of this process leads to genomic instability and cancer.
My focus is on the pathology and natural history of prostate, testicular and penile cancer working to translate basic research into practical treatments for patients with novel tests and bespoke predictive treatments.
I am interested in all the strategies cancer cells adopt to proliferate and evade cell death, in order to develop new therapeutic strategies. Specifically, my research focuses on how cancer cell metabolism affects tumour growth and investigating how inflammation can drive malignant transformation.
My group is interested in epigenetic regulation of somatic mutagenesis in normal and malignant B cells. We aim to understand how alterations in the nuclear envelope influence B cell chromatin conformation, and what the epigenetic consequences of these alterations are.
My research focuses on kinases regulating cancer cell growth and motility to understand how and when to target them with drugs. My group is currently examining the role of the PKN kinases in malignant progression.
My research interests lie in the area of translational bioinformatics. Current research projects are focused in high-throughput data analysis, integration with clinical data, databases and software development, particularly for pancreatic cancer and breast cancer.
My research focuses on molecular pathology of pancreatic cancer, in particular its development and progression. We are using this knowledge to develop biomarkers for early, non-invasive detection of this malignancy in urine specimens.
My research group uses unique proteomics and computational approaches to understand how cell signalling pathways driven by the activity of protein kinases contribute to the development of cancer. Increasing this knowledge will be invaluable in advancing personalised cancer therapies.
My group works on developing novel approaches to improve efficacy and safety of allogeneic stem cell transplantation and adoptive immunotherapy as treatments for blood cancers. We focus on T-cell alloreactivity in the context of stem cell transplantation and immunotherapy.
We are interested in understanding the cellular and molecular mechanisms that promote cancer cell plasticity and adaptation of tumour cells in metastatic niches and under therapeutic pressure.
My group aims to discover the epigenetic changes taking place during cancer initiation and develop potential drugs that can prevent these changes which may be abnormal but reversible, before many damaging mutations occur.
Our group studies changes in metabolism and metabolic stresses that are caused by oncogene activation and how these stresses lead to tumour suppressive responses.
My research interests focus on mechanisms of disease initiation and maintenance and the identification and validation of novel therapeutic targets in myeloid leukaemias.
Our goal is to identify mechanisms that support haematopoietic stem cell function and understand how the leukaemic stem cells “play” with these mechanisms to thrive.
We are investigating how drug resistance evolves in bowel and gastro-oesophageal cancers, how these tumour types can be treated more effectively through novel immunotherapies and targeted drugs, and how treatment sensitivity and resistance can be predicted.
Our research group focuses on understanding how centrosome amplification impacts tumour progression and how we can target cells with amplified centrosomes to develop new cancer therapies.
My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
We are interested in how cancer cells interact with each other and the microenvironment. We investigate how cancer cell communication with neighbouring stromal cells and the extracellular matrix can impact on invasion and response to targeted therapies, to try to block cancer progression, with a particular focus on breast and pancreatic cancer.
My lab focuses on discovering functions of phosphorylation induced by damaged DNA in normal and cancer cells, and investigating the role of different phosphorylation events in cancer development.
I am interested in studying the effects of the inflammatory microenvironment on disease progression and resistance to treatment in haematological malignancies with emphasis on survival and mechanisms of treatment resistance in chronic lymphocytic leukaemia and B cell lymphoma.
My research in breast cancer focuses on the progression of in-situ to invasive disease with the aims of identifying 1) markers which can predict behaviour and 2) novel therapeutic targets.
Our group focuses on understanding the molecular and cellular mechanisms that mediate resistance to anti-cancer therapies in breast cancer. We are interested in dissecting the microenvironmental cues that orchestrate specific tumour responses and metastasis formation.
We study the role of growth factor receptor signalling and intracellular trafficking (movement inside cells) in tumour growth and metastasis in the view of improving cancer therapy.
The central aim of our laboratory is to understand the biology of leukaemic stem cells and identify therapeutic targets to specifically eradicate them, thus discovering novel and efficient leukaemia therapies. We also focus on understanding haematopoietic stem cell biology with the hope to harness this knowledge for expanding them for therapeutic purposes.
My studies concentrate on the immunogenetics of human B cell malignancies, such as chronic lymphocytic leukaemia, follicular lymphoma and the role for B cell receptor in the pathogenesis of B cell lymphoma and leukaemia.
I am the Module Lead for 3 undergraduate Biomedical Science Modules. I am also the Cancer Theme Lead for MBBS with direct responsibility for Year 2 Cancer Week. In addition, I supervise MSc project dissertations.
Our lab aims to improve treatments for women with ovarian cancer, particularly those that are resistant to chemotherapy. We are interested in developing therapies that can adapt to the evolution of chemotherapy resistance over time such as Adaptive Therapy.
We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
My lab utilises state-of-art multi-omics methodologies to study how protein synthesis is dysregulated in cancer cells, and how this dysregulation contributes to various stages of cancer progression.
Our research group is involved in investigating nuclear and mitochondrial DNA repair as a therapeutic target in cancer. In particular, we have focused on the DNA mismatch repair (MMR) pathway, the system for recognising and repairing mistakes in DNA replication and so preventing genetic mutations.
My lab aims to understand the mechanisms that underlie numerical and structural chromosome aberrations in cancer at a molecular level, which also involves understanding how normal cells replicate and segregate their genomes.
Our main research areas are focused on understanding the evolution of Barrett’s oesophagus to cancer, field cancerisation of the human stomach, and clonal expansion in ductal carcinoma in situ of the human breast.
The overarching goal of our laboratory is to understand the biology of normal haematopoietic and leukaemic stem cells in order to selectively kill cancer stem cells for better leukaemia treatment.
My research focuses on understanding the genetic and molecular mechanisms that underlie the initiation and progression of B-cell non-Hodgkin’s lymphomas in order to define clinically-relevant biomarkers.
My group studies how different populations of immune cells in the tumour microenvironment cross-talk in order to establish a tumour-supportive niche in metastasis. This research aims to identify more effective therapeutic targets in metastatic cancers.
I am a leading expert in establishing higher education degrees for acquiring operative surgical skills by simulation. I pioneered the Masters course in Surgical Skills and Sciences at Barts Cancer Institute and have set up a “Virtual Reality Surgical Simulation Centre” for training surgeons.
The focus of our research is the tumour microenvironment and we are particularly interested in understanding the composition and function of the tumour extracellular matrix in immunosuppression. Cancer types we focus on include ovarian and breast cancers.
My lab aims to understand the alterations in metabolism that take place in cancer and investigate whether extrinsic factors, such as diet, influence cancer metabolism and disease trajectory. We then want to uncover whether these dependencies can be exploited therapeutically.
My main research interests are in genital and urinary cancers, leading a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.
My focus is on detailed translational trials in pancreatic cancer, with a focus on targeting the tumour microenvironment. Our aim is to define what perturbations occur in tumours of patients receiving trial drugs.
My laboratory research explores alternative pre-mRNA splicing in prostate cancer (PCa) biology, and liquid biopsy-derived molecular biomarkers of treatment outcomes.
Our research group is interested in uncovering the molecular mechanisms regulating tissue growth, invasion and metastasis using the fruit fly Drosophila melanogaster as a genetically tractable model organism.
My major research interest is understanding the metabolism of chronic lymphocytic leukaemia and lymphoma with the aim that this will underpin the development of the next generation of anti-metabolic drugs for these diseases.
My main research interests are in haematopoietic stem cells (HSCs) and leukemic initiating cells. I seek to understand how intrinsic and extrinsic signals are integrated by normal and malignant stem cells.
Our research focuses on how the cytoskeleton of cancer cells regulates transcriptional rewiring during tumour growth and dissemination. We aim to understand how such rewiring affects the tumour microenvironment.
My research interests focus on improving the care of women with breast cancer through clinical trials. I am investigating a variety of novel agents that target specific pathways within cancer cells and the surrounding tissue.
My research focuses on kinase biology and how kinase signalling pathways are hijacked in cancer. We combine computational biology with proteomics and cell biology to uncover novel ways to target these dysregulated networks.
My group studies how RNA-mediated mechanisms, in particular long noncoding RNAs, regulate cell division and how dysregulation of these processes leads to genome instability and cancer.
My research focuses on the development of radiopharmaceuticals for imaging and therapy of cancer, and translating these to the clinic
My main research interest is in exploring why ASS1 is aberrantly expressed in human cancers and how this knowledge may be exploited for anticancer therapy. I lead an active translational programme from bench to bedside of the arginine-depleting agent ADI-PEG20 in several hard-to-treat cancers.
I have broad research interests and experience in bioinformatics, cancer genomics and data analytics. These research areas mainly involve developing and applying bioinformatics and computational approaches to analyse large-scale cancer datasets to uncover novel diagnostic and prognostic biomarkers. I also lead the Cancer Research UK Barts Centre Bioinformatics Core Facility.
We work on cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses, in particular focusing on replicating adenovirus and vaccinia virus.
My group combines mathematics, computer simulations and genomic information to study evolutionary processes. We aim to understand how a tumour’s evolutionary history is reflected in its genome, how evolution can be quantified in individual tumours and how this information predicts future evolution.
My research focuses on the fundamental aspects of leukaemia initiating cell (LIC) biology in adult acute lymphoblastic leukaemia, with the aim of gaining fundamental insight into the underlying biology of LICs to reveal dependencies that are tractable targets for therapy.
I am a clinical collaborator in numerous laboratory-based studies particularly the localisation of Lipiodol in Hepatocellular carcinomas, inflammatory and immune responses to surgery, and tumour-stroma interactions in pancreatic carcinoma. Clinical areas of interest have been video consultations in tertiary care, surgery for pancreatic tumours (especially NETs) and liver tumours, and tissue banking.
My main research interests have included how malignant cancers are able to invade, spread and metastasise and my research has focused on gaining a better understanding of the mechanisms involved in cancer progression.
My main interests are the development of improved therapy for lymphoma and leukaemia. I am Emeritus Gordon Hamilton Professor of Medical Oncology in the Barts and the London School of Medicine and Dentistry, Queen Mary University of London.
My main interests are in cancer imaging and imaging of endocrine disease. I am currently Professor Emeritus at the Barts Cancer Institute in Queen Mary University of London
My research interests include clonal evolution in colorectal adenomas and inflammation-associated cancer, the nature of Barrett’s glands, and the design of methods to explore neutral drift in stem cell divisions in normal human tissues.
My research is focused on Machine Learning with applications in Bioinformatics and Health Informatics, and Data Management of the Breast Cancer Now Tissue Bank (BCNTB).
My research is focused on studying changes in metabolism and metabolic stresses that are caused by oncogene activation and how these stresses lead to tumour suppressive responses.
My research focuses on understanding the progression of early breast cancer (ductal carcinoma in situ – DCIS) to invasive disease and the role of the microenvironment in this process.
I am a bioinformatician and am currently developing a computer vision pipeline to quantify and characterise tumour hypoxia in squamous cell carcinomas.
The aim of my research project is to identify and functionally characterise candidate disease genes in familial leukaemia.
The primary focus of my research is to establish a platform for a neo-antigens-based vaccine for triple-negative breast cancer and pancreatic cancer.
My work is currently focused on lymphoma, working on variant calling and gene expression analysis of NGS data.
My research is primarily focused on exploring how the bone marrow niche regulates haematopoietic stem cell development and leukaemia progression.
My project is focused on investigating the role of gland phenotype in the evolution of Barrett’s oesophagus to dysplasia.
My research is focused on understanding the early stages of breast cancer by using normal human breast cells obtained through the Breast Cancer Now tissue bank as building blocks to recreate a human breast duct in the laboratory environment.
My work is based on studying signalling networks in AML primary samples in order to predict responses to kinase inhibitors.
Our research focuses on the use of modified, replicating oncolytic Vaccinia viruses and adenoviruses armed with immune-modulatory genes such as cytokines to create a self-propagating treatment for tumours that results in long-term immunological memory to the tumour cells.
My research focuses on novel strategies to enrich, isolate and characterise a chemo-resistant population in patients with follicular lymphoma.
My research is focused on describing the mechanisms underlying Lamin B1 nuclear disassembly in B-cell normal development and how a dis-regulated Lamin B1 removal pathway could lead to several haematological malignancies within the germinal centre in secondary lymph organs.
In 2015 I was awarded a research associate position funded by Cancer Research UK to join Dr Sanz-Moreno for my postdoc, where I develop my research studying the crosstalk between the cytoskeleton and mitochondria during tumour progression and invasion.
My work focuses on the global analysis of miRNA in pancreatic cancer and developing miRNA biomarkers for early detection of this malignancy.
My research is focused on the role of lipid metabolism in resistance to therapy in acute myeloid leukemia.
I am involved in some projects that are focused in the stroma components of a tumour, particularly the endothelial vessels, and its potential role in some key processes including chemotherapy or metastasis.
My project focuses on understanding how the proteins involved in RNA binding and alternative splicing of pre-mRNA are regulated.
My areas of interest are imaging biochemical processes such as metabolism/proliferation (microPET), and the use of in vivo preclinical imaging in a range of applications.
We are updating the bioinformatics data management system, expanding the analytical modules and functionalities, developing purpose-built graphical pug-ins and designing the bioinformatics infrastructure to allow the querying and analysis of data returned from projects using BCNTB tissues.
My project is focused on the identification of molecular factors affecting adenoviral therapy.
My research project aims to investigate the inflammatory cytokine IL-6 as a major target in high grade serous carcinoma, with the hope of identifying targeted therapies for treatment.
My research looks at if/how invasive traits and metabolism of amoeboid versus mesenchymal cancer cells are altered in response to tissue mechanics, with the aim of developing anti-metastasis treatment(s).
My research projects involve identifying tumour suppressors involved in regulating the hypoxic response and metabolic stress, with the aim to identify novel targeted therapies against these.
My research activity aims to characterise lncRNAs involved in the maintenance of genomic stability and to understand how their dysregulation can lead to cancer development.
My work is focused on producing systematic classification of phosphorylation sites detectable by mass spectrometry that will provide new insights into the complexity and topology of kinase signalling.
We are investigating the metabolic dependencies of cancer cells under biologically relevant conditions, such as nutrient stress, in a biomarker-specific manner. I use metabolomics, proteomics and other cutting-edge platforms to dissect the metabolic architecture of cancer models that harbour alterations in tumour suppressors that drive disease trajectory and treatment response.
Our research is focused on metabolic stresses accompanying activation of oncogenes. We are investigating cell responses to metabolic stresses in order to deeply understand these mechanisms and propose metabolic targets for cancer therapies.
My research involves the conjugation and radiolabelling of antibodies, small proteins and peptides with radioisotopes followed by HPLC/TLC validation and in vitro radioligand binding assays.
I am a Bioinformatician working on the development of pipelines for NGS data analysis, including mutational calling, Single-Cell RNA-seq, ChIP peak calling and methylation, variant annotation and prioritisation, as well as multi-layer data integration strategy and tools.
My research is focused on the tumour microenvironment of ovarian cancer with a particular focus on the extracellular matrix and how current and novel treatments influence this microenvironment.
My research in Prof Balkwill’s group focuses on imaging tumour-associated macrophages and other immune cells in live ex vivo tumour slices, in order to assess their behaviour and the impact of immunotherapies on the live tumour microenvironment.
My focus is on investigating the epigenetic regulation of the PI3K pathway and identifying an effective combination therapy that will disable compensatory bypass routes, overcoming drug resistance.
I am interested in cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses.
My research will focus on studying Myosin II function during melanoma progression and its cross-talk with inflammatory and immune responses.
My research focuses on designing 3D in vitro models to understand the contribution of the tumour microenvironment during HGSOC progression.
My research project aims to integrate multi-omic molecular and histological data datasets of the microenvironment of HGSOC metastases. This work will allow us to identify key microenvironmental components and pathways that sustain and promote tumours.
My research is focused on investigating how the epitranscriptome regulates normal and malignant haematopoiesis.
My work focuses on the influence of PKN2 on the immune-microenvironment, and the invasion and metastasis of pancreatic ductal adenocarcinoma in vivo, using murine models.
My project aims to identify strategies to boost host anti-cancer immune response through enhanced oncolytic efficiency of oncolytic viruses by small molecules.
I investigate mathematical properties of somatic evolution in the context of both cancerous and healthy tissue.
My research is focused on understanding how integrins help cancer cells invade and metastasise, as well as how we can use integrins as biomarkers of disease and therapeutic targets.
My research focuses on how we can therapeutically target integrins to modulate angiogenesis in heart failure.
Our group has shown that internalised c-Met traffics through endomembranes positive for LC3B and Beclin1. Furthermore, c-Met sustains signalling from Autophagy Related Endomembranes, ARE. We hypothesised therefore that the AREs supporting c-Met trafficking and signalling belong to a novel non-canonical pathway.
My current research is focused on the clonal evolution of human colorectal cancers arising in inflammatory bowel disease using multi-omic data, with the aim of understanding fundamental underlying dynamics of tumour growth and progression.
We are using single cell multi-omic approaches to study how cancer cell plasticity and the tumour microenvironment contribute to metastasis in colorectal cancer.
I am developing SNPnexus, a software dedicated to improving our understanding of the functional role of genetic variations to prioritise clinically relevant ones facilitating the promise of precision medicine.
My project focuses on identifying phosphorylation regulated interactions of DNA Damage repair proteins, and investigating the functional role of these interactions for DNA damage repair and cancer development.
I am investigating the role of the microenvironment on gland phenotype in the evolution of Barrett’s oesophagus to dysplasia.
My research focuses on exploring why ASS1 is differently expressed in human cancers and how this information may be transferred for anticancer therapy.
My work will identify other players in the regulation of angiocrine signalling using a CRISPR screen. I will also explore the molecular mechanisms underlying how FAK controls angiocrine signalling.
My project focuses on the translation reprogramming in acute myeloid leukaemia upon stresses such as chemotherapy.
My research focuses on the perturbation of EMT-like pathways in follicular lymphoma and chronic lymphocytic leukaemia and how this promotes cancer propagation, transformation into a more aggressive form of disease and resistance to therapy.
My research project aims to identify germline mutations in families with leukaemia of unknown aetiology and study the intra and inter leukaemia heterogeneity observed in these families, through examination of clonal evolution and secondary genetic events.
The aim of my work is to develop clinically-relevant biomarkers that could aid in earlier disease detection, predict treatment response, and inform clinical management of patients.
My research is focused on understanding the role of contractility in pancreatic cancer.
I am interested in understanding whether epigenetics can play a driving role in the transition from normal to transformed cells in the breast.
Using the fruit fly, Drosophila melanogaster, I aim to dissect the role played by protein phosphatases in regulating the tissue growth controlling Hippo signalling pathway, which has commonly been implicated in cancer development, progression and metastasis.
I am studying how the tumour suppressor gene LIMD1 functions in the microRNA pathway, a gene regulatory pathway that is often dysregulated in cancer.
We are using a variety of molecular and cytological techniques to study the mechanisms underlying chromosomal instability (CIN) in high grade serous ovarian cancer (HGSOC) that allow these highly adaptable tumours to become drug resistant.
My research investigates a specific composition of extracellular matrix molecules which may explain the difference between responders and non-responders to immunotherapy.
My role focuses on the design and implementation of a data management system for a pancreatic tissue bank hosted by the Institute.
My interest also lies in the development of various web-based computational analyses and data mining tools for biological research.
My project looks at the modelling of cancer for improved therapy development. I am carrying out in vivo cancer experiments, with and without modifications of the tumour microenvironment, to examine effects of such treatments on anti-cancer therapy efficacy.
My project looks at the metabolic mechanisms of drug resistance in acute myeloid leukaemia (AML). We look to understand what makes certain cells more vulnerable to AML treatment and how we can use this to improve overall treatment strategies.